300 related articles for article (PubMed ID: 27861725)
1. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.
Nishino M; Ramaiya NH; Hatabu H; Hodi FS; Armand PF
Br J Haematol; 2018 Mar; 180(5):752-755. PubMed ID: 27861725
[No Abstract] [Full Text] [Related]
2. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
[TBL] [Abstract][Full Text] [Related]
3. [Ring-shaped lesions on a lung scan].
Coşkuntürk M; Aarntzen EHJG; van der Velden WJFM
Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30719883
[TBL] [Abstract][Full Text] [Related]
4. A Cascade of Pembrolizumab-Induced Autoimmune Toxicities with Mixed Responses to Corticosteroids.
Habib R; Gordon J; Zielinski R
J Thorac Oncol; 2018 Jan; 13(1):e8-e9. PubMed ID: 29258672
[No Abstract] [Full Text] [Related]
5. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis.
Frye BC; Meiss F; von Bubnoff D; Zissel G; Müller-Quernheim J
N Engl J Med; 2020 Jun; 382(26):2573-2574. PubMed ID: 32579820
[No Abstract] [Full Text] [Related]
7. Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.
Rickard F; Hyams C; Low AT
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29735504
[TBL] [Abstract][Full Text] [Related]
8. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.
Ortega Sanchez G; Jahn K; Savic S; Zippelius A; Läubli H
J Immunother Cancer; 2018 Sep; 6(1):85. PubMed ID: 30176946
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab.
Eun Y; Kim IY; Sun JM; Lee J; Cha HS; Koh EM; Kim H; Lee J
Sci Rep; 2019 Oct; 9(1):14039. PubMed ID: 31575933
[TBL] [Abstract][Full Text] [Related]
10. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.
Shea M; Rangachari D; Hallowell RW; Hollie NI; Costa DB; VanderLaan PA
Cancer Treat Res Commun; 2018; 15():17-20. PubMed ID: 30207283
[TBL] [Abstract][Full Text] [Related]
11. Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non-Small-Cell Lung Cancer.
Yaga M; Shiroyama T; Hirata H; Oya K; Takeda Y; Kumanogoh A
Clin Lung Cancer; 2022 Mar; 23(2):e116-e117. PubMed ID: 34980563
[No Abstract] [Full Text] [Related]
12. Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report.
Miao K; Xu Y; Xu W; Zhang Y; Xu Y; Tian X; Zhang L
Thorac Cancer; 2021 Aug; 12(15):2214-2216. PubMed ID: 34145962
[TBL] [Abstract][Full Text] [Related]
13. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
Andersson NW; Zachariae C; Simonsen AB
Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
[No Abstract] [Full Text] [Related]
14. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
Fiset PO; Shapera S; Butler MO; Tsao MS
Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
[No Abstract] [Full Text] [Related]
15. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
Li X; Cheng Y; Zhang M; Yan J; Li L; Fu X; Zhang X; Chang Y; Sun Z; Yu H; Zhang L; Wang X; Wu J; Li Z; Nan F; Tian L; Li W; Young KH
J Hematol Oncol; 2018 Jan; 11(1):15. PubMed ID: 29386072
[TBL] [Abstract][Full Text] [Related]
16. Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant Pseudomonas aeruginosa Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.
Oltolini C; Ripa M; Andolina A; Brioschi E; Cilla M; Petrella G; Gregorc V; Castiglioni B; Tassan Din C; Scarpellini P
Mycopathologia; 2019 Feb; 184(1):181-185. PubMed ID: 30101407
[TBL] [Abstract][Full Text] [Related]
17. A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy.
Park ESY; Rabinowits G; Hamnvik OR; Dagi LR
J AAPOS; 2018 Aug; 22(4):310-312. PubMed ID: 29626663
[TBL] [Abstract][Full Text] [Related]
18. Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab.
Boudjemaa A; Rousseau-Bussac G; Monnet I
J Thorac Oncol; 2018 Mar; 13(3):e39-e40. PubMed ID: 29472057
[No Abstract] [Full Text] [Related]
19. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
20. PD-1 inhibitor induced alopecia areata.
Guidry J; Brown M; Medina T
Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
